Doctors Without Borders/Médecins Sans Frontières (MSF) applauds today’s news that the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the tuberculosis (TB) drug bedaquiline beyond when its primary patent expires in July. The rejection is a significant step toward increasing access to the lifesaving TB drug. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
80
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
30
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
450
bottom of page
Comments